Security Snapshot

Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (VRXAW) Institutional Ownership

CUSIP: H9130A111

13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

13

Shares (Excl. Options)

4.14MFull value: 4,135,300 · shares · 30 Sep 2026

Price

$0.06

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,130,813
Value change
+$427,389
Number of holders
13
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
141,303,920
SEC-reported price per share
$0.03
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • VRXAW - Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share is tracked under CUSIP H9130A111.
  • 13 institutions reported positions in Q3 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 26 to 13 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $992.5KFull value: $992,502 · USD · 30 Jun 2026
    to
    $617.26KFull value: $617,262 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 13 institutions filings for Q3 2026.

Open SEC evidence

Security key

H9130A111

13F reference period

Q3 2026

13F holders

13

13D/G owners

4

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
VRXAW
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Deck David Lukas 18% 25,502,836 Deck David Lukas 10 Jun 2026
Xlife Sciences AG 16% 23,029,967 Xlife Sciences AG 10 Jun 2026
European Molecular Biology Laboratory 16% 22,891,235 European Molecular Biology Laboratory 10 Jun 2026
Schoeni Gilbert Edgar 16% 22,539,749 Schoeni Gilbert Edgar 10 Jun 2026
As of 30 Sep 2026, 13 institutional investors reported holding
4.14MFull value: 4,135,300 · shares · 30 Sep 2026
shares of Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (VRXAW). This represents 2.9% of the company’s total
141.3MFull value: 141,303,920 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
2
Headline period
Q3 2026
Rows shown
1-2 of 2
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 4,135,300 $617,262 +$427,389 $0.06 13
2026 Q2 8,886,388 $992,502 +$964,573 $0.11 26
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .